Spero inks $105M financing deal with KKR affiliate
- Spero Therapeutics (SPRO) said that it secured $105M in non-recourse, non-dilutive financing from affiliates of Healthcare Royalty, a business of KKR (KKR).
- The proceeds will primarily fund the Phase 2 development of SP001, Spero's lead immunology candidate, a third-generation anti-CD40L monoclonal antibody
How it works
Once you click Generate, Ollama reads this article and crafts 5 comprehension questions. Your answers are graded against the article content — general knowledge won't be enough. Score 70+ to count toward your certificate.
Questions are cached — you'll always get the same 5 for this article.